Pixyl delivers quantitative neuroimaging biomarker extraction for improved insight and decision-making in clinical studies. Our automatic neuroimaging solutions are designed for seamless integration into both web-based and locally deployed CRO platforms. Advanced algorithms are available for multiple sclerosis, chronic stroke, and traumatic brain injury applications.
Efficient time management for image reviewers
Objective analysis reduces variability across entire study database for better decision-making
Correlated with expert opinion
Longitudinal studies to assess treatment efficacy. Consistent quantitative results for quality assurance
Pôle Anesthésie-Réanimation. CHU Grenoble
"Pixyl has been selected for the randomized trial OxyTC that I coordinate on a national level (PHRC National 2013).This multicenter study comprises of 23 sites and 300 patients who have serious traumatic brain injury. The purpose of the study is to measure the effect of brain oxygenation optimization on brain lesion volume (primary endpoint)."
PH Responsable Unité Neuro-Vasculaire. CHU Grenoble
"Numerous studies suggest that lesion volume should be a biomarker for neurological recovery. Indeed, lesion volume, whether or not it is associated with neurological
deficiency, is an independent predictor of recovery.
Recent development of high resolution MRI sequences allows for a more precise analysis of lesions, and this further motivates the study of stroke lesion volume. However, even with these developments, volume measurement requires manual delineation. This is a long task, difficult to reproduce, and unthinkable for large study populations.
Even though other segmentation software claims to perform automatic delineation, none have been validated or seem usable in routine. That's why we contributed to the development of Pixyl software solutions that allow automatic, fast and precise delineation of cerebral infarction."